Recipharm
Recipharm hassigned a partnership agreement with Follicum in preparation for a clinical trial of the drug candidate FOL-005.
Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.
“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” said Jan Alenfall, CEO of Follicum.
“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” said Maria Lundberg, general manager of Recipharm in Solna.